X4 Pharmaceuticals Inc Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Unidentified Participant - Stifel - Analyst : Hi all. This is [Helen] on for Steve. Just two quick questions from me. So first you mentioned that you're focused on implementing home-health visits for patients enrolled in the Waldenstrom's Trial, you're going to mitigate some of the effects from COVID. Is that same strategy being applied to the WHIM and SCN trials as well and if so how is that going? Thanks.

Question: Unidentified Participant - Stifel - Analyst : Okay. That make sense. And then can you provide any updates regarding X4P-003, X4P-002. Are either of these assets in IND -- enabling studies at this point? And then also can you just remind us how those two assets are being differentiated from each other? I know 002 is engineered across the blood-brain barrier but I was just wondering if you could give a little more color on 00 -- 003? Thank you.

Question: Unidentified Participant - Stifel - Analyst : Okay. Great. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 05, 2020 / 1:30PM, XFOR.OQ - Q3 2020 X4 Pharmaceuticals Inc Earnings Call

Question: Arlinda Lee - Canaccord Genuity - Analyst : Hi guys. I was hoping that you could provide an update on the enrollment for the WHIM syndrome? And then I also feel curious on preclinical programs. Might we be expecting any data presentations on this anytime in the near future? Thank you.

Question: Arlinda Lee - Canaccord Genuity - Analyst : Great. Thank you.

Question: Unidentified Participant - Stifel - Analyst : Hi guys. This is [Shawn] on for Joel. Thank you for taking my questions. Two from me today. First on Waldenstrom's (inaudible) data in the first-half next year, maybe just talk about how you plan to roll out that data? And then kind of getting into the reason may be what the results could be. Aside from seeing any complete responses, are there any biomarkers that would give you confidence that any efficacy signals we see are due to your drug and not the combo? And then a follow-up on WHIMS, and maybe if you could talk about patient identification, where you're kind of at right there and how many patients are on your EAP program right now? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 05, 2020 / 1:30PM, XFOR.OQ - Q3 2020 X4 Pharmaceuticals Inc Earnings Call

Question: Unidentified Participant - Stifel - Analyst : Great. Thank you so much Paula.

Question: Unidentified Participant - Stifel - Analyst : Hi. Good morning team. This is [Sato] on for Mayank. Congrats on all the progress. Just a few questions from us this morning. First off as it relates to the Waldenstrom's program and now expecting the data first-half next year, is this more a sort of enrollment related more than anything else in terms of you know, monitoring responses and should we still expect date on that you know, 12-to-18 patient range?

Question: Unidentified Participant - Stifel - Analyst : No, no. That's exactly right. Yes.

Question: Unidentified Participant - Stifel - Analyst : Great. That's helpful. And maybe just a brief follow-up as it relates to the SCN program. Can you just remind us, is this still a single-site in Washington I believe, on ClinicalTrials.gov? And then you know, given the - [I mean the] compromised nature of the patients how do you plan to sort of manage enrollment concerns you know, acknowledging that 14 days is that short treatment window and maybe at-home visits don't meet because much sense here?

Question: Unidentified Participant - Stifel - Analyst : Great. That's really helpful. Thanks for taking our questions. And congrats for the progress.

Question: Unidentified Participant - Stifel - Analyst : Hey, good morning everyone. This is [Arthur] for RK. So I just have a quick question or the follow-up on the WM strategy. So could you guys remind us, the dose level across the patient and what can we read through from the WHIM syndrome study in terms of the optimal dose level for...

Question: Unidentified Participant - Stifel - Analyst : ... the WM? Thank you. Yes.

Question: Unidentified Participant - Stifel - Analyst : Yes. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 05, 2020 / 1:30PM, XFOR.OQ - Q3 2020 X4 Pharmaceuticals Inc Earnings Call

Question: Unidentified Participant - Stifel - Analyst : ... (inaudible)...

Question: Unidentified Participant - Stifel - Analyst : Yes, yes. Thank you very much for that.

Question: Laura Christianson - Cowen - Analyst : Hi. Good morning guys. Thanks for taking my question. On Waldenstrom's, I was wondering if you could just talk a little bit more about how we expect mavorixafor might fit into the treatment paradigm if it's approved, just what's the potential for mavorixafor for it to be used first line in combination with ibrutinib and CXCR4-positive (inaudible) patients?

Question: Laura Christianson - Cowen - Analyst : Perfect. And then just a quick one for Adam. I'm wondering how the -- that purchase agreement that you recently put in place, how that might impact your expected cash runway?

Question: Laura Christianson - Cowen - Analyst : Perfect. That's helpful. Thanks.

Question: Zegbeh Jallah - ROTH Capital Partners - Analyst : Good morning guys. Thanks for the update. I think I'm probably just going to ask one again about the preclinical pipeline with Art on board, as you mentioned. Just kind of want to know you know, how you expect to kind of leverage his broad expertise, do you plan to broaden out the pipeline or pursue additional indications with some of your earlier line preclinical programs?

Question: Zegbeh Jallah - ROTH Capital Partners - Analyst : Thanks Paula. And then just a follow-up here. I'm not even sure if you can you can answer this one but I think on the last call we had, you noticed that we weren't capping patients that were pre-treated or not pre-treated for the Waldenstrom's study, which is [going to try roll into] what you said. But can you provide any comments on if you're enrolling more pre-treated patients or are you enrolling more [non patients]?

Question: Zegbeh Jallah - ROTH Capital Partners - Analyst : Thank you.